ENAGenomicsUNIVERSITY OF CALIFORNIA, SAN DIEGOhttps://www.ebi.ac.uk/ena/browser/view/PRJNA1183459Homo sapiensLocally advanced cervical cancer remains an area of high therapeutic unmet need, with ~50% of patients developing disease recurrence despite treatment with chemotherapy combined with radiation. Combination of immune checkpoint blockade with chemoradiation has been explored in this setting, but optimal sequencing of these modalities is unknown. To address this question, we developed and conducted the NCI sponsored trial "Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer_, randomizing patients to atezolizumab administration prior to and concurrent with chemoradiation therapy (CRT) vs. concurrent with CRT (NRG-GY017 N=40, ClinicalTrials.gov Identifier: NCT03738228). Patients were... (for more see dbGaP study page.)ENAfalseNRG-GY017: Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical CancerNRG-GY017: Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer2025-09-242025-04-29PRJNA11834599606